Explore our
BioLizard and AbnomX announce partnership
BioLizard and AbnomX announce a strategic partnership to accelerate antibody discovery. Combining BioLizard’s advanced analytics with AbnomX’s Antibody-Extractor platform, the collaboration empowers scientists to transform immune repertoire data into actionable insights.
From enigma to insight: How explainable AI can help us unravel biological complexity
Discover how explainable AI helps scientists move beyond black-box predictions to uncover the why behind biological insights. Learn how BioLizard’s Bio|Mx platform combines transparency, AI, and human expertise to drive smarter, data-informed R&D decisions.
Strategic AI for single cell sequencing & multi-omics advances
Discover how AI is revolutionizing single cell sequencing and multi-omics research. Learn how BioLizard’s Bio|Mx platform blends AI innovation with human expertise to unlock deeper biological insights, accelerate drug discovery, and advance precision medicine.
BioLizard joins BioWin
BioLizard has joined BioWin, Wallonia’s leading health cluster, to collaborate with innovators in biotech, medtech, and research. This partnership strengthens our mission to leverage data for better health outcomes and accelerate life sciences innovation in the region.
AI in the life sciences: (Un)limited potential?
Explore the potential and challenges of AI in drug discovery. BioLizard highlights the importance of high-quality data, human-AI collaboration, and tailored strategies to transform complex biomedical data into actionable insights for more efficient and effective R&D.
BioLizard announces the appointment of André van de Sande as Chairman of the Board
BioLizard appoints André van de Sande as Chairman of the Board. With 30 years of global life sciences experience and a proven track record in pharma, biotech, and consulting, André will guide BioLizard’s international expansion and support its mission in bioinformatics and data-driven life sciences.
BioLizard announces Swiss subsidiary and service offering for AI-powered digital transformation of life sciences at Biopôle in Lausanne
BioLizard launches Swiss subsidiary BioLizard SA at Biopôle in Lausanne, expanding its international presence. The new office offers AI-powered digital transformation services, bioinformatics, and multi-omics solutions to support Swiss biotech clients in drug discovery, diagnostics, and research.
Trends in single cell sequencing: Spatial transcriptomics
Spatial transcriptomics is emerging as a key trend in single cell sequencing, offering powerful insights into tissue biology and tumor microenvironments. Despite challenges in cost, complexity, and analytics, growing standardization will drive adoption. BioLizard already leads in expert analysis.
Trends in single cell sequencing: Atlases & public data
The rise of atlases and public single cell datasets is transforming research by reducing costs, accelerating hypothesis generation, and enriching proprietary data. With expert integration, these resources enable faster target discovery, model selection, and data-driven decisions.
Trends in single cell sequencing: High-throughput technologies
High-throughput single cell sequencing enables millions of cells to be analyzed in parallel at lower cost, boosting large-scale screening, diagnostics, and rare disease research. With expert analytics, it drives robust insights, but strategic planning is essential for success.